MedTrace Logo

RGD PET/MRI in Sporadic Vestibular Schwannoma

NCT03393689 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-01-10

No results posted yet for this study

Summary

The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E\[c(RGDyK)\]2 in patients with sporadic Vestibuarl Schwannomas.

Conditions

  • Acoustic Neuroma

Interventions

DRUG

One injection of 68Ga-NODAGA-E[c(RGDyK)]2

One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Hjalte C.R. Sass, MD, Ph.d.-Fellow · Rigshospitalet, Denmark

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-02
Primary Completion
2021-01-02
Completion
2021-01-02

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03393689 on ClinicalTrials.gov